Celgene

FDA delays BMS’ liso-cel decision, citing COVID-19 travel restrictions

BMS picked up liso-cel 9 (lisocabtagene maraleucel) following its $74bn takeover of Celgene last year – the CAR-T therapy is one of the key assets critical to the potential payout ... BMS also agreed similar conditional payments, dependent on approval,

Switzerland: a life sciences hub

Celgene, now a subsidiary of Bristol-Myers Squibb (BMS), recently built its second production plant in Couvet, followed by the construction of a third production site in Boudry (Neuchâtel), to produce

Janssen scores another expansion for new Darzalex combination in the US

It also has an approval for another combination regimen made up of Darzalex, Celgene’s Revlimid (lenalidomide) and dexamethasone, for the treatment of newly diagnosed multiple myeloma patients who are ineligible

BMS pays $475m for Dragonfly’s IL-12 immunotherapy programme

Dragonfly also signed a deal with Celgene, now owned by BMS, in 2017 and 2018 for a series of candidates focused on the treatment of blood cancers.

Bristol-Myers Squibb’s revenues rise on Celgene acquisition

The increase, said BMS, was primarily driven by the impact products gained from its acquisition of Celgene, which completed in November 2019. ... BMS’ biggest seller was its multiple myeloma therapy Revlimid (lenalidomide), which it added to its

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]